(Q50577396)

English

HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?

scientific article published in December 2005

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

title

HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy? (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

1 reference

Andrew J Muir

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

language of work or name

English

0 references

publication date

1 December 2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

published in

Nature Reviews Gastroenterology & Hepatology

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

volume

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

issue

12

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

page(s)

568-569

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

exact match

https://scigraph.springernature.com/pub.10.1038/ncpgasthep0337

0 references

cites work

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0337

retrieved

21 January 2018

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1038%2FNCPGASTHEP0337

retrieved

21 January 2018

Identifiers

DOI

10.1038/NCPGASTHEP0337

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

PubMed publication ID

16327834

1 reference

stated in

Europe PubMed Central

PubMed publication ID

16327834

retrieved

15 March 2018

reference URL

http://europepmc.org/abstract/MED/16327834

(Q50577396)

HCV genotype 2 and 3 infections: what is the optimal duration for peginterferon alpha-2b and ribavirin therapy?

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)